BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics. A rival posted encouraging data on a drug that outperformed ...
Truist upgraded Walmart (WMT) to Buy from Hold with a price target of $89, up from $76. Walmart continues to gain share ...
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Evonik, whose products are used in items from animal feed and diapers to Pfizer/BioNTech's COVID ... saw a double-digit share price rise of... Ideally, your overall portfolio should beat the market ...
The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...